人乳头瘤病毒疫苗接种。
Vaccination against human papillomavirus.
作者信息
Mello Claudia Figueiredo
出版信息
Einstein (Sao Paulo). 2013 Dec;11(4):547-9. doi: 10.1590/s1679-45082013000400027.
Abstract
Human papillomavirus infection is common and causes different manifestations. This infection is a public health concern because it has been associated with genital tract malignant diseases among men and women. Currently two vaccines are available to prevent the human papillomavirus infection and its associated diseases.
摘要
人乳头瘤病毒感染很常见，并会引发不同的表现。这种感染是一个公共卫生问题，因为它与男性和女性的生殖道恶性疾病有关。目前有两种疫苗可用于预防人乳头瘤病毒感染及其相关疾病。
相似文献
1
Vaccination against human papillomavirus.人乳头瘤病毒疫苗接种。
Einstein (Sao Paulo). 2013 Dec;11(4):547-9. doi: 10.1590/s1679-45082013000400027.
2
Epidemiology and prevention of Human Papillomavirus.人乳头瘤病毒的流行病学与预防
Ann Ig. 2018 Jul-Aug;30(4 Supple 1):28-32. doi: 10.7416/ai.2018.2231.
3
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
4
[Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].[墨西哥人乳头瘤病毒疫苗接种政策定义的建议。世界卫生组织战略咨询专家组]
Salud Publica Mex. 2009 Jul-Aug;51(4):336-41. doi: 10.1590/s0036-36342009000400011.
5
Vaccination: A durable design.疫苗接种：一种持久的设计。
Nature. 2012 Aug 30;488(7413):S7. doi: 10.1038/488S7a.
6
Papillomavirus vaccine for women, and for men?人乳头瘤病毒疫苗是用于女性的，还是也用于男性？
Med Clin (Barc). 2019 Apr 5;152(7):264-265. doi: 10.1016/j.medcli.2018.11.012. Epub 2018 Dec 24.
7
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.24至45岁女性四价人乳头瘤病毒（6、11、16、18型）重组疫苗的安全性、免疫原性及有效性：一项随机双盲试验
Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.
8
Clinical approval: Trials of an anticancer jab.临床批准：一种抗癌注射剂的试验。
Nature. 2012 Aug 30;488(7413):S4-6. doi: 10.1038/488S4a.
9
Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.在日本，九价 HPV 疫苗对女童和妇女进行常规和补种接种的公共卫生影响和成本效益：基于模型的研究。
BMC Infect Dis. 2021 Jan 6;21(1):11. doi: 10.1186/s12879-020-05632-0.
10
Human papillomavirus vaccines.人乳头瘤病毒疫苗
Dermatol Ther. 2009 Mar-Apr;22(2):150-7. doi: 10.1111/j.1529-8019.2009.01227.x.
引用本文的文献
1
Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy.变革癌症治疗：在免疫治疗新时代释放病毒疫苗、单克隆抗体和蛋白酶靶向嵌合体的力量。
ACS Omega. 2024 Feb 5;9(7):7277-7295. doi: 10.1021/acsomega.3c06501. eCollection 2024 Feb 20.
2
Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development.基于合成生物学的细胞工程在诊断、治疗和药物研发中的应用。
Signal Transduct Target Ther. 2023 Mar 11;8(1):112. doi: 10.1038/s41392-023-01375-x.
3
Cancer vaccines as promising immuno-therapeutics: platforms and current progress.癌症疫苗作为有前途的免疫疗法：平台和当前进展。
J Hematol Oncol. 2022 Mar 18;15(1):28. doi: 10.1186/s13045-022-01247-x.
4
Recombinant protein vaccines, a proven approach against coronavirus pandemics.重组蛋白疫苗，对抗冠状病毒大流行的成熟手段。
Adv Drug Deliv Rev. 2021 Mar;170:71-82. doi: 10.1016/j.addr.2021.01.001. Epub 2021 Jan 7.
5
Involvement of Human Papillomaviruses in Cervical Cancer.人乳头瘤病毒与宫颈癌的关系
Front Microbiol. 2018 Nov 28;9:2896. doi: 10.3389/fmicb.2018.02896. eCollection 2018.
6
Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.设计和开发疫苗、药物和治疗方法以对抗人类乳头瘤病毒的进展。
Front Immunol. 2018 Nov 12;9:2478. doi: 10.3389/fimmu.2018.02478. eCollection 2018.
本文引用的文献
1
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.四价人乳头瘤病毒（HPV）疫苗在男性 HPV 感染和疾病中的功效。
N Engl J Med. 2011 Feb 3;364(5):401-11. doi: 10.1056/NEJMoa0909537.
2
FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).美国食品药品监督管理局批准二价人乳头瘤病毒疫苗（HPV2，佳达修）用于女性，并更新了免疫实践咨询委员会（ACIP）的 HPV 疫苗接种建议。
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9.
3
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.四价人乳头瘤病毒（6/11/16/18型）疫苗对高级别宫颈和外生殖器病变持续预防效果的汇总分析。
Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.
4
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.人乳头瘤病毒（HPV）16/18 AS04佐剂疫苗预防致癌性HPV型别所致宫颈感染和癌前病变的疗效（PATRICIA）：一项针对年轻女性的双盲随机研究的最终分析
Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6.
5
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
Zotero 插件